TY - JOUR AU - Shen, Chiung-Chyi AU - Cheng, Wen-Yu AU - Lee, Chung-Hsin AU - Dai, Xue-Jun AU - Chiao, Ming-Tsang AU - Liang, Yea-Jiuen AU - Hsieh, Wan-Yu AU - Mao, Tsuo-Fei AU - Lin, Guo-Shi AU - Chen, Shou-Ren AU - Liu, Bai-Shuan AU - Chen, Jun-Peng PY - 2020 DA - 2020/07/29 TI - Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment JO - BMC Cancer SP - 709 VL - 20 IS - 1 AB - It has previously been shown that bevacizumab, when added to chemotherapy, improved overall survival in several cancers. In glioblastoma multiforme (GBM), bevacizumab increased progression-free survival and it is widely used for tumor recurrence, though it has failed to improve overall survival (OS) in controlled trials. However, an effective biomarker for predicting the prognosis of bevacizumab treatment has yet to be identified. This study, therefore, aimed to retrospectively analyze the polymorphisms of p53 codon 72 and the clinical characteristics of GBM specimens from Taiwanese patients. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-020-07210-8 DO - 10.1186/s12885-020-07210-8 ID - Shen2020 ER -